ClinicalTrials.gg

Program

Propylene Glycol

Also written as “Propylene Glycol (0.6%)”, “Nanodrop®” and “Propylene Glycol, 0.6% eye drops”.

Its studies are mostly in Dry Eye Syndromes, led by 3 companies.

Furthest: phase 4, since Oct 18, 20133 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon10 open or runningno phasesince Oct 18, 2013Oct 18, 2013none ahead
Andover Research Eye Institute11 open or runningphase 4since Jun 24, 2026Jun 24, 2026none ahead
Laboratorios Sophia S.A de C.V.10 open or runningphase 2since Sep 30, 2019Sep 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2013First study: no phase study in Dry Eye SyndromesNew to AlconAlcon · NCT01967147 · 279 enrolled
  2. Sep 30, 2019Laboratorios Sophia S.A de C.V.'s first study: phase 2 study in Dry Eye SyndromesNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT04111965 · 126 enrolled · Mexico
  3. Jun 24, 2026Andover Research Eye Institute's first study: phase 4 study in Dry Eye SyndromesNew to Andover Research Eye InstituteAndover Research Eye Institute · NCT07676084 · 60 planned · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07676084Dry Eye Syndromes · United States4RecruitingAndover Research Eye InstituteOct 202660
NCT04111965Dry Eye Syndromes · Mexico2CompletedLaboratorios Sophia S.A de C.V.Dec 10, 2021126
NCT01967147Dry Eye Syndromes–CompletedAlconJan 2015279

How it is read

Names in the registry

  • “Propylene Glycol (0.6%)”, 1 entry
  • “Nanodrop®”, 1 entry
  • “Propylene Glycol, 0.6% eye drops”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.